SNSergei Valeryevich Nikitin

Sergei Valeryevich Nikitin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sergei Valeryevich Nikitin has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effect of 5-hydroxypyrimidine derivatives on the antitumor effect of gemcitabine, hematological parameters, and survival of mice with adenocarcinoma Ca755

    by Руслан Журиков, Лариса Коваленко, Светлана Алексеева, Сергей Никитин, Андрей Дурнев

    Introduction. The combined use of cytostatic agents with drugs from other groups is a promising method for reducing hematotoxicity. Aim. To evaluate the impact of 5-hydroxypyrimidine derivatives and gemcitabine, as well as their combinations, on tumor growth inhibition, survival, and hematological parameters in animals with Ca755 adenocarcinoma. Materials and methods. After inoculation of adenocarcinoma Ca755 mice received SNK-411, SNK-578, gemcitabine or their combination from 2nd to 15th day of tumor development. Tumor volume was measured and tumor growth inhibition was calculated on the 9th, 16th and 21st days of tumor development. On the 22nd day, half of the animals were left for follow-up and evaluation of survival, while the other half was euthanized, and their blood samples were taken for analysis. Results. Compared to the intact control, a decrease in hemoglobin and erythrocyte levels was observed in all experimental active control groups that received SNK-411, SNK-578, and gemcitabine. The administration of 5-hydroxypyrimidine derivatives in combination with gemcitabine prevented the suppression of hematopoiesis. No statistically significant differences were found in platelet and leukocyte counts among the groups. Tumor growth inhibition (TGI) was studied on 7th day after the 14-day administration of SNK-411. In the group that received SNK-411 TGI was 45 %, in the group that received SNK-578 — 53%, in the group treated by gemcitabine — 61 %. 14-day combined administration of SNK-411 and gemcitabine resulted in 79 % TGI. Combination of SNK-578 and gemcitabine inhibited tumor growth by 80 %. Gemcitabine increased median survival time (MST) by 44 %, SNK-411 — by 18 %, SNK-578 — by 21 %. Combinations of SNK-411 and gemcitabine increased MST by 62 %, SNK-578 and gemcitabine — by 71 %. Conclusion. The combination of gemcitabine and 5-hydroxypyrimidine derivatives demonstrated prominent antitumor effect without hematotoxicity. Введение. Совместное применение цитостатиков с лекарственными препаратами из других групп является перспективным методом снижения гематотоксичности. Цель. Оценить влияние производных 5-оксипиримидина и гемцитабина, а также их комбинаций на торможение роста опухоли, выживаемость и гематологические показатели животных с аденокарциномой Ca755. Материалы и методы. Мыши линии C57BL после инокуляции аденокарциномы Ca755 получали СНК-411, СНК-578, гемцитабин или их комбинации со 2-го по 15-ый день развития опухоли. На 9, 16 и 21 день развития опухоли измеряли объем и рассчитывали торможение роста опухоли. На 22-ой день половину животных отсадили для исследования выживаемости, вторую половину животных вывели из эксперимента и взяли кровь для анализа. Результаты. В экспериментальных группах активного контроля и при введении СНК-411, СНК-578 и гемцитабина отмечено снижение содержания гемоглобина и эритроцитов по сравнению с интактным контролем. Введение производных 5-оксипиримидина совместно с гемцитабином препятствовало угнетению кроветворения. Различия содержания тромбоцитов не выходили за пределы референсных значений. В межгрупповых показателях лейкоцитарной формулы не было выявлено значимых различий. Через 7 дней после 14-ти дневного введения СНК-411 торможение роста опухоли (ТРО) составило 45 %, у СНК-578 ТРО составило 53 %, введение гемцитабина вызывало торможение роста опухоли на 61 %. При курсовом введении СНК-411 совместно с двукратным введением гемцитабина ТРО составило 79 %. Совместное введение СНК-578 с гемцитабином вызывало торможение роста опухоли на 80 %. Увеличение продолжительности жизни (УПЖ) при введении гемцитабина составило 44 %, при введении СНК-411 — 18 %, при введении СНК-578 — 21 %. Совместное введение гемцитабина с СНК-411 вызывало увеличение продолжительности жизни на 62 %, сочетание введения СНК-578 с гемцитабином — на 71 %. Заключение. Комбинация гемцитабина с производными 5-оксипиримидина позволила получить выраженный противоопухолевый эффект без проявлений гематотоксичности.


  • Open Access

    Anti-inflammatory properties of 5-hydroxypirimidine derivatives on the model of CFA-induced paw and ankle joint edema in rats

    by R. V. Zhurikov, L. P. Kovalenko, S. V. Nikitin

    Anti-inflammatory potency of 5-hydroxypyrimidine derivatives SNK-411 (2-isobutyl-4,6-dimethyl-5-hydroxypirimidine) and SNK-578 (hydrochloride 2-isobutyl-4,6-dimethyl-5-hydroxypirimidine) was evaluated on the model of complete Freund`s adjuvant (CFA)-induced exudative inflammation in experiment on 60 outbreed male rats weighing 180–200 g in comparison with prednisolone. Prednisolone, SNK-411 and SNK-578 were injected twice: in 24 and 2 hours in before the injection of CFA. Prednisolone was administered in dose of 10 mg/kg, SNK-411 in doses of 25 mg/kg and 40 mg/kg, SNK-578 in doses of 10 mg/kg and 25 mg/kg. Paw and ankle joint edema were registered 24 hours after subplantar injection of CFA in right hind foot. Prednisolone administration in dose of 10 mg/kg decreased paw and ankle joint edema, SNK-578 in dose of 25 mg/kg decreased exudative edema of the paw, SNK-411 in dose of 40 mg/kg decreased paw and ankle joint edema. Acquired data correlates with previously obtained results that 5-hydroxypirimidine derivatives have antiallergenic effect on the model of systemic anaphylaxis in experiment on guinea pigs.

  • Open Access

    EFFECTS OF 5-HYDROXYPYRIMIDINE DERIVATIVE ON GROWTH AND METASTASIS OF MELANOMA B16 IN C57BL/6 MICE

    by R. V. Zhurikov, L. P. Kovalenko, S. V. Nikitin, A. D. Durnev

    Introduction. Suppression of activation of an alternative immune response is promising approach of tumor immunotherapy. In this study we evaluated antitumor and antimetastatic activity of SNK-411.Objective. Evaluation of antitumor and antimetastatic activity of 5-hydroxypyrimidine derivative SNK-411 in mouse melanoma B16 model.Materials and methods. Antitumor and antimetastatic activity of the SNK-411 were studied in tests on male C57BL/6 mice using the B16-F10 melanoma model. SNK-411 was injected intraperitoneally at doses of 10 and 25 mg/kg from day 2 to day 15 of melanoma development. Doxorubicin was injected at dose of 4 mg/kg on day 2 of tumor development to act as positive control. Antitumor and antimetastatic activity were studied by calculation of tumor growth inhibition and metastasis inhibition index (MII).Results. SNK-411 at doses of 10 and 25 mg/kg and in combination with single injection of doxorubicin in dose of 4 mg/kg showed antimetastatic activity. MII in SNK-411 at 10 mg/kg dose was 72 %, at dose of 25 mg/kg was 82,9 %. The combination of 14-day course of intraperitoneal injections of SNK-411 at dose of 10 mg/kg and injection of doxorubicin 4 mg/kg revealed MII 97,1 %, in half of mice in this group metastasis were not observed on 21st day of melanoma development. All results are statistically significant. There was no significant inhibition of tumor growth in all groups.Conclusion. SNK-411 has antimetastatic activity in tests on melanoma B16 model. Further investigation is required.


  • Open Access

    Evaluation of allergenic properties and immunotoxicity of dipeptide mimetic of brain-derived neurotrophic factor GSB-106

    by L. P. Kovalenko, K. V. Korzhova, R. V. Zhurikov, C. B. Nikitin, A. D. Durnev, С. В. Никитин

    Исследование аллергизирующих свойств и иммунотоксичности готовой лекарственной формы дипептидного миметика мозгового нейротрофического фактора ГСБ-106

  • Sustainable Flow Synthesis of Encoded Beads for Combinatorial Chemistry and Chemical Biology

    by Hongxia Hu, Sergei Valeryevich Nikitin, Adam Bjørnholdt Berthelsen, Frederik Diness, Sanne Schoffelen, Morten Meldal

    Monosized beads of polar resins were synthesized for combinatorial chemistry and chemical biology by sustainable microchannel flow synthesis. Regular, biocompatible and optically encoded beads could be efficiently prepared on large scale and in high yield. In a preparative flow polymerization instrument, taking advantage of a designed T-connector for droplet formation, quality beads were synthesized with accurate size control using a minimal amount of recirculating silicon oil as suspension medium. Bead-size was controlled through shear imposed by the silicon oil flowrate. This process provided 86 % yield of ~500 m macrobeads beads within a 20 m size range with no deformities or vacuoles, ideally suited for combinatorial chemistry and protein binding studies. The simple flow equipment consisted of a syringe pump for monomer and initiator delivery, a T-connector, a gear pump for oil recirculation, a long, heated coil of Teflon tubing and a collector syringe. The method was used for preparation of PEGA1900 beads, optically encoded with fluorescent microparticles. The microparticle matrix (MPM) encoded beads were tested in a MPM-decoder showing excellent recognition in bead decoding.